Convatec Group Plc · LSE:CTEC
Convatec — 10M 2025 Earnings Presentation
9 slides from Convatec's earnings presentation, Nov 13, 2025
Slide 1: New products drive broad-based growth
13 Nov 2025 New products drive broad-based growth On track to deliver targets Trading update for the ten months ended 31 October 2025
Slide 2: Disclaimer
Disclaimer For the purposes of this notice, “Presentation” means this document, its contents or any part of it, any oral presentation, any question or answer session and any written or oral material discussed or distributed before, during or after the Presentation meeting. This information, which do
Slide 3: Hosts
Hosts Jonny Mason Fiona Ryder Chief Executive Officer Chief Financial Officer 3
Slide 4: Broad-based revenue growth
Broad-based revenue growth Jan-Oct 2025 FY25 guidance Organic revenue growth1 Continued broad-based growth; on track to deliver 6.3%2 6.0-6.5%2 targets. Reported revenue growth of 6.2% ex-InnovaMatrix®2 Advanced Wound Care Strong growth in North America, led by ConvaFoamTM, MSD2 MSD2 and in GEM. Eur
Slide 5: On track to deliver 2025 financial targets
On track to deliver 2025 financial targets Previously • Unchanged guidance for each category: AWC: MSD Organic revenue growth1 ex-InnovaMatrix®2 6.0-6.5% 5.5-7.0% ex-InnovaMatrix®; OC: MSD; CC: M/HSD; IC: DD FY24: 7.7% • InnovaMatrix®: around $70m revenue Adjusted operating Unchanged • Further opera
Slide 6: Strategic progress
Strategic progress Advanced Wound Care Ostomy Care • Strong growth in North America, led by ConvaFoamTM • Good growth in North America, Europe & GEM • Building European ConvaFoamTM momentum • Esteem BodyTM performing strongly and winning share • Rich pipeline: ConvaNioxTM, ConvaFiberTM & ConvaVacTM
Slide 7: 2026 outlook
2026 outlook Organic revenue 5-7%1 • New products driving broad-based growth growth1 ex-InnovaMatrix® • In 2026 InnovaMatrix® ≤2% of Group revenue Adjusted operating Further • Further simplification and productivity benefits margin progress • Mix & operating leverage from organic revenue growth Adju
Slide 8: Summary
Summary Continued resilience • Business performing well and in-line with expectations • New product launches delivered strong sales growth, offsetting market headwinds • Broad-based growth across all categories FY25: on track to deliver our financial targets • Narrowed revenue guidance to 6.0-6.5% o
Slide 9: &
& 9